We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK (GSK) Stock Moves -0.55%: What You Should Know
Read MoreHide Full Article
In the latest trading session, GSK (GSK - Free Report) closed at $35.89, marking a -0.55% move from the previous day. This move was narrower than the S&P 500's daily loss of 1.37%. Elsewhere, the Dow lost 1.29%, while the tech-heavy Nasdaq lost 1.87%.
Heading into today, shares of the drug developer had gained 3.03% over the past month, outpacing the Medical sector's loss of 4.07% and the S&P 500's loss of 4.93% in that time.
Wall Street will be looking for positivity from GSK as it approaches its next earnings report date. On that day, GSK is projected to report earnings of $1.03 per share, which would represent a year-over-year decline of 5.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.63 billion, up 4.42% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.79 per share and revenue of $37.08 billion. These totals would mark changes of +9.54% and -6.63%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GSK. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.44% lower within the past month. GSK currently has a Zacks Rank of #3 (Hold).
In terms of valuation, GSK is currently trading at a Forward P/E ratio of 9.51. This represents a discount compared to its industry's average Forward P/E of 17.04.
Meanwhile, GSK's PEG ratio is currently 1.9. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. GSK's industry had an average PEG ratio of 2.06 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GSK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK (GSK) Stock Moves -0.55%: What You Should Know
In the latest trading session, GSK (GSK - Free Report) closed at $35.89, marking a -0.55% move from the previous day. This move was narrower than the S&P 500's daily loss of 1.37%. Elsewhere, the Dow lost 1.29%, while the tech-heavy Nasdaq lost 1.87%.
Heading into today, shares of the drug developer had gained 3.03% over the past month, outpacing the Medical sector's loss of 4.07% and the S&P 500's loss of 4.93% in that time.
Wall Street will be looking for positivity from GSK as it approaches its next earnings report date. On that day, GSK is projected to report earnings of $1.03 per share, which would represent a year-over-year decline of 5.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.63 billion, up 4.42% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.79 per share and revenue of $37.08 billion. These totals would mark changes of +9.54% and -6.63%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GSK. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.44% lower within the past month. GSK currently has a Zacks Rank of #3 (Hold).
In terms of valuation, GSK is currently trading at a Forward P/E ratio of 9.51. This represents a discount compared to its industry's average Forward P/E of 17.04.
Meanwhile, GSK's PEG ratio is currently 1.9. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. GSK's industry had an average PEG ratio of 2.06 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GSK in the coming trading sessions, be sure to utilize Zacks.com.